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INVITED COMMENTARY
Thomas L. Forbes, MD, London, Ontario, Canada
Although vascular surgeons recognize that atherosclerosis is a
systemic disease, we are frequently reminded that our practical
application of this knowledge has been less than ideal. The current
article is no exception. The PREVENT III investigators enrolled
1404 patients with critical limb ischemia from 83 North American
centers in a prospective, randomized, multicenter trial of edifoli-
gide for the prevention of vein graft failure. With publication of
graft-related outcomes pending, this article examined the relation-
ship between medical comorbidities, perioperative medical thera-
pies, and the 30-day incidence of mortality, myocardial infarction,
and cerebrovascular events. There were no specific inclusion crite-
ria with respect to medical therapies; this allowed the authors to
examine the contemporary medical management of patients with
advanced lower extremity atherosclerotic disease.
Their findings are sobering, to say the least. Although one
fourth of patients had encountered a vascular surgeon previously
while undergoing lower extremity revascularization, one third
were not receiving antiplatelet agents, and half were not taking
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-blockers or lipid-lowering agents at the time of study entry. This
improved somewhat at discharge, when 80% and 60% of patients
were receiving antiplatelet drugs and -blockers, respectively. The
rate of lipid-lowering therapy remained alarmingly low at discharge
despite the growing body of evidence supporting the role of statins
in preventing mortality, cardiovascular morbidity, and graft occlu-
sions. It seems that in our attempts to salvage limbs, we have been
less than attentive to the systemic nature and treatment of the
underlying atherosclerotic disease.
Several other observations deserve comment. The periopera-
tive initiation of such medical therapies was less frequent in non–
university-affiliated hospitals. Additionally, although African
Americans were more prone to hypertension and renal failure, they
were less likely to be receiving antithrombotic and lipid-lowering
agents upon admission and were less likely to receive antiplatelet
agents at the time of discharge after lower extremity revasculariza-
tion. This may represent a further underappreciation of the sys-
temic aspects of atherosclerosis in this group, which is younger and
more commonly female, although the authors correctly point out
that additional socioeconomic factors may be contributing as well.
Vascular surgeons are increasingly viewed as the primary
vascular specialists for patients with lower extremity ischemia
and, as such, must implement operative, interventional, and
medical therapies when indicated. I share the authors’ concern
regarding the underutilization of medical therapies in patients
with critical ischemia despite numerous published supporting
reports. Although treatment guidelines may be helpful in sum-
marizing this evidence, they are not entirely necessary if we
more rigorously adhere to what we have already learned over the
last several years.
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